Johnson & Johnson EPS - Earnings per Share 2010-2022 | JNJ

Johnson & Johnson annual and quarterly earnings per share history from 2010 to 2022. Earnings per share can be defined as a company's net earnings or losses attributable to common shareholders per diluted share base, which includes all convertible securities and debt, options and warrants.
  • Johnson & Johnson EPS for the quarter ending March 31, 2022 was $1.93, a 16.81% decline year-over-year.
  • Johnson & Johnson EPS for the twelve months ending March 31, 2022 was $7.42, a 31.1% increase year-over-year.
  • Johnson & Johnson 2021 annual EPS was $7.81, a 41.74% increase from 2020.
  • Johnson & Johnson 2020 annual EPS was $5.51, a 2.13% decline from 2019.
  • Johnson & Johnson 2019 annual EPS was $5.63, a 0.36% increase from 2018.
Johnson & Johnson Annual EPS
2021 $7.81
2020 $5.51
2019 $5.63
2018 $5.61
2017 $0.47
2016 $5.93
2015 $5.48
2014 $5.70
2013 $4.81
2012 $3.86
2011 $3.49
2010 $4.78
2009 $4.40
Johnson & Johnson Quarterly EPS
2022-03-31 $1.93
2021-12-31 $1.77
2021-09-30 $1.37
2021-06-30 $2.35
2021-03-31 $2.32
2020-12-31 $0.65
2020-09-30 $1.33
2020-06-30 $1.36
2020-03-31 $2.17
2019-12-31 $1.50
2019-09-30 $0.66
2019-06-30 $2.08
2019-03-31 $1.39
2018-12-31 $1.12
2018-09-30 $1.44
2018-06-30 $1.45
2018-03-31 $1.60
2017-12-31 $-3.91
2017-09-30 $1.37
2017-06-30 $1.40
2017-03-31 $1.61
2016-12-31 $1.38
2016-09-30 $1.53
2016-06-30 $1.43
2016-03-31 $1.59
2015-12-31 $1.14
2015-09-30 $1.20
2015-06-30 $1.61
2015-03-31 $1.53
2014-12-31 $0.89
2014-09-30 $1.66
2014-06-30 $1.51
2014-03-31 $1.64
2013-12-31 $1.22
2013-09-30 $1.04
2013-06-30 $1.33
2013-03-31 $1.22
2012-12-31 $0.90
2012-09-30 $1.05
2012-06-30 $0.50
2012-03-31 $1.41
2011-12-31 $0.09
2011-09-30 $1.15
2011-06-30 $1.00
2011-03-31 $1.25
2010-12-31 $0.70
2010-09-30 $1.23
2010-06-30 $1.23
2010-03-31 $1.62
2009-12-31 $0.79
2009-09-30 $1.20
2009-06-30 $1.15
2009-03-31 $1.26
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $465.705B $93.775B
Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among pharma companies. J&J's worldwide business is divided into three segments: Pharmaceutical, Medical Devices and Consumer. The company has several drugs covering a broad range of areas such as neuroscience, cardiovascular & metabolism, immunology, oncology, pulmonary hypertension and infectious diseases and vaccines. The Medical Devices Segment offers products in the orthopedics, surgery, interventional solutions and vision markets. The Consumer Segment segment includes a broad range of products covering the areas of baby care, beauty/skin health, oral care, wound care and womens' health care, as well as over-the-counter (OTC) pharmaceutical products.
Stock Name Country Market Cap PE Ratio
Pfizer (PFE) United States $294.404B 10.27
Eli Lilly (LLY) United States $283.955B 33.50
AbbVie (ABBV) United States $266.851B 11.70
Merck (MRK) United States $236.570B 13.36
Novartis AG (NVS) Switzerland $200.009B 14.40
GlaxoSmithKline (GSK) United Kingdom $113.161B 13.21
Novo Nordisk (NVO) Denmark $0.000B 32.07